Splenic Disease in Dogs: Welfare Considerations

Key Welfare Considerations

• The spleen is commonly affected by benign haematomas and malignant haemangiosarcoma in older large-breed dogs.
• Splenic masses may be clinically silent until rupture causes haemoabdomen, a life-threatening emergency.
• German Shepherd Dogs, Golden Retrievers, and Labrador Retrievers have elevated haemangiosarcoma risk.
• Clinical signs of splenic rupture include acute collapse, pale mucous membranes, and abdominal distension.
• Welfare impact of acute haemoperitoneum is severe — dogs experience rapid deterioration and shock.
• Emergency stabilisation with intravenous fluids and transfusions is required before surgical intervention.
• Splenectomy is the definitive treatment, with survival depending on the underlying pathology.
• The '2/3 rule' suggests approximately 2/3 of splenic masses are malignant haemangiosarcoma.
• Post-splenectomy survival for haemangiosarcoma averages 1-2 months without adjuvant chemotherapy.
• Doxorubicin-based chemotherapy may extend median survival to 4-6 months in haemangiosarcoma.
• Quality of life assessment post-surgery should guide treatment intensity decisions.
• Early detection through regular abdominal ultrasound in predisposed breeds improves welfare outcomes.
• Owners should be counselled on acute signs of splenic rupture to enable rapid emergency response.
• Palliative care focusing on comfort and quality of life is appropriate when surgery is declined.
• End-of-life welfare planning should be discussed proactively in dogs with known splenic masses.